Aim: To document the use of prescribed psychoactive medicines in France in patients recovering from alcohol use disorders (AUDs). Method: Survey among short-and long-term abstainers attending groups of French self-help associations for AUDs, recording socio-demographic profile, duration of abstinence, prescription of psychoactive medication and attitudes towards that, and whether or not in medical or psychological follow-up for AUD. Result: Five hundred seventy-five abstainers participated. More than a half had stopped drinking for at least 5 years. About 25% of the very long-term abstainers were still in follow-up. Benzodiazepines, then antidepressants, were the most frequently used medication. Prescriptions of medication decreased with length of abstinence; was always higher in women than in men and in those with a medical follow-up. About 45% claimed that they were 'dependent' on their pills. Ten years after having stopping drinking, 19 and 42.1% of men and women, respectively, were still under medication. Cluster analysis of self-opinion on medication showed that in~30% of the subjects medication seemed to be prescribed for precautionary reasons. Conclusion: Psychoactive medication in France is frequently prescribed for years following alcohol withdrawal. While it is possible that this is over-prescription, and further work in this regard is needed, changes in an on-going treatment for a given patient would need to be cautious. Short summary: Psychoactive medication in alcohol use disorders often prescribed for long-term abstainers in France. Benzodiazepines and antidepressants are the most frequently prescribed drugs. Prescription is more frequent in women and in those subjects having medical follow-up for their alcohol problem. Over-prescription is discussed.
INTRODUCTION
Whether it is the immediate recovery plan, or arises after the failure of attempts at controlled drinking, becoming a long-term abstainer is the aim of many of those who had become dependent on alcohol. After withdrawal from alcohol, the challenge is to prevent relapse, and medications to aid that goal are licensed in many countries: acamprosate, disulfiram and naltrexone. However, besides these specific drugs, psychoactive medication such as anxiolytics and antidepressants are widely prescribed, apparently to alleviate the anxious and depressive symptoms often accompanying alcohol use disorder (AUD), both before and after alcohol withdrawal (Nalpas et al., 2016) . There is no recommended length of psychoactive medication prescription following stopping drinking since various parameters, which vary from one patient to another, are to be taken into account. Moreover, psychoactive medication, particularly benzodiazepines, can induce dependence (Lader, 1983) , so their use should be restricted ideally to withdrawal (Lejoyeux et al., 1998) . Apart from studies in the immediate 3-12 months post withdrawal, there seem to be no published randomized trials of antidepressants (or benzodiazepines) among long-term abstinent alcoholics and is little to guide clinicians advising those patients.
There are long-term studies of health status and abstinence after stopping drinking, including hundreds of patients over 7-20 years (e.g. Blonigen et al., 2009; Gual et al., 2009; Kaskutas et al., 2009; Kim et al., 2012; Mertensa et al., 2012; Pagano et al., 2013; ) but, unfortunately, none of them provided information regarding the prescription of psychoactive medication.
In a previous study performed on alcoholics seeking treatment in a specialized addiction care center, we reported that there were psychoactive medication prescriptions following alcohol withdrawal in 54.2% of men and 69% of women who had stopped drinking for >2 years (Nalpas et al., 2016) . To understand this high rate, its evolution over time and the risks of dependence, we designed a survey that would include many long-term abstainers, to ask about prescription medication and how they evaluated their treatment.
SUBJECT AND METHODS
This research program was managed by the Alcohol Working Group of INSERM (French National Institute for Health and Medical Research), which brings together representatives of the nine main mutual-aid ('self-help') associations for AUD in France and researchers in addiction to stimulate community-based participatory research. Representatives of the self-help associations for AUD and scientific researchers designed the research program, which was piloted by the working group before implementation.
Subjects
Participants were recovering alcoholics who attended support meetings of one of the six self-help associations for AUD who agreed to participate in the survey: Alcool Assistance, Alcool-Joie et Santé, Amis de la Santé, Amitié-Présence RATP, Croix Bleue, Santé de la Famille, Vie libre. (Alcoholic Anonymous (AA) opted out lest participation conflicted with AA's Traditions). All these associations recommend complete abstinence from alcohol.
Method
Questionnaire details A structured anonymous questionnaire was adapted from that in our previous study (Nalpas et al., 2016) and requested:
• Socio-demographic: age, sex, marital status (couple/alone), employment status (yes/no) and accommodation (stable/precarious).
• Drinking status: no/yes and duration of abstinence.
• Smoking status: current smoker or not.
• Current follow-up for their AUD by a physician and/or a psychologist specialized or not in addiction treatment.
• Medication prescribed by a physician and taken at the time of the survey using a list based on the Anatomical Therapeutic Chemical classification from which we selected the drugs currently used in France belonging to the sub-classes: N03 (antiepileptics), N05 (antipsychotics+ anxiolytics+ hypnotics and sedatives), N06 (antidepressants) and N07 (other nervous system drugs including those used in addictive disorders). The corresponding 57 principal psychoactive medicinal products, including those for alcohol and tobacco withdrawal, were listed on a separate sheet alphabetically sorted by brand name on the front of the page and by generic name (INN) on the other side; each medicinal product corresponded to a given number which was the same for the brand and the generic name. Subjects were asked to report which medicinal products were taken on the day of the survey and the duration of treatment (1 week, 1-2 weeks, 2-4 weeks, 1-3 months, 3-6 months, >6 months).
• How they considered their treatment: reminder of the AUD (yes/ no); support needed (yes/no); intended to cure the causes of the AUD (yes/no); intended to cure the consequences of the AUD (yes/no); help to avoid relapses (yes/no).
• Self-evaluation of dependence on the treatment (Likert scale ranging from 0 to 5).
Procedure
The questionnaire was printed using a specific template. After completing, the document was folded and one of the sides contained the return address; postage was pre-paid. Representatives of each self-help association used the association's network to invite sites to participate; the number of sites approached was not recorded. Finally, 79 sites throughout France agreed to participate. The number of questionnaires sent to each meeting was defined by their usual number of attendees. Questionnaires were distributed by the leader at the beginning of the meeting. Two thousand questionnaires were sent at the beginning of March 2015; the dead-line for return was 30 June 2015. We did not collect information on the reasons for refusal to participate nor the proportion of the questionnaires sent out that were actually distributed.
Statistical analysis
Data were computerized using an adapted form. Analyses were performed using the SPSS V22.0 software (IBM SPSS Inc., Armonk, New York, USA). Quantitative and qualitative parameters were described using mean (±SD) and percent distribution, respectively. Quantitative variables were compared using variance analysis and qualitative ones using the Chi 2 test. In order to identify whether patients can be grouped according to the way they consider their medications, we performed a cluster analysis of the four questions relative to this domain using the two-step cluster procedure. A P value <0.05 was considered as significant.
RESULTS

Socio-demographic
Five hundred and seventy-five subjects, 413 men (73.1%) and 152 women (26.9%) returned a questionnaire, 27.5% of the 2000 sent out to the sites. Subjects mean age was 56.4 ± 10.7 years, without any difference according to sex (M 56.7 ± 10.9; W 55.8 ± 10.3). Most (59.5%) were living in couples, two-thirds (64.4%) were unemployed or retired and most (89.2%) had stable housing (Table 1) .
Abstinence and medical care
The duration of abstinence from alcohol ranged from <1 month to >10 years. Fifty-five participants (9.7%) did not provide information on this item. Subjects were divided into four categories: <1 year of abstinence (20.2%), 1-5 years (25.3%), 5-10 years (17.1%), >10 years (37.5%) (Table 1) . Altogether, 54.5% reported at least 5 years of abstinence. Mean age increased with the duration of abstinence, ranging from 50.7 ± 9.3 to 63.7 ± 8.6 in those with very short and very long-term abstinence, respectively. More than a half (55.6%) claimed that they were under the care of a physician for their AUD, and one-third (33.5%) were still visiting a psychiatrist or psychologist for that same reason (Table 1) . Crosssectional analysis of these follow-up data showed that 21.5% and 1.9% had medical or psychological follow-up only, while 31.7% had both. The frequency of being followed-up, whatever the modality, decreased significantly (P < 0.0001) according to the length of abstinence: 92.4% and 23.5% in those having stopped drinking since <1 year and >10 years, respectively (data not shown).
The rate of subjects receiving medication among those being medically followed-up for their AUD was strikingly and significantly higher until year 5 after alcohol withdrawal as compared to those who were not (73.2 vs 34.0%, P < 0.001); thereafter the difference was reduced (35.7 vs 22.6%) but remained statistically different (P = 0.04).
Medication according to the duration of abstinence
On the day of the survey 45.1% (n = 255) was receiving medication, more women than men (56.6% vs 40.9%, P = 0.001).
Medication was categorized in six groups: anxiolytics, antidepressants, hypnotics, abstinence support, antipsychotics and anti-epileptics. The main category prescribed was anxiolytics (26.9%), then antidepressants (21.9%); in all cases except one the anxiolytic belonged to the benzodiazepine family. Women received significantly more anxiolytics, antidepressants and antipsychotics than men (Table 2 ). About twothirds (64.2%) of the medication were taken for over 6 months.
The proportion of subjects receiving at least one medicinal product significantly decreased with the duration of abstinence ( Fig. 1 A  and B , black line). In men (Fig. 1 A) , the most striking decrease concerned medication to support abstinence which fell from 37% at year 1 of abstinence to 1.5% at year 5 and more. While 45.2%, 32.9% and 16.4% received an anxiolytic, an anti-depressant or a hypnotic at year 1, respectively, these rates fell to 11.7, 5.9 and 5.9%, respectively, at year 10 and more.
In women, Fig. 1B shows close to that observed in men for medication to support abstinence and for hypnotics. Regarding anxiolytic drugs, their rate increased, although not significantly, until year 5, plateaued up to year 10 and decreased thereafter, but still remained higher than in men (26.3 vs 11.7%, P < 0.001). The rate of antidepressants taken at year 1 (43.3%) did not change up to year 5; then it decreased to 23.7% at year 10 and more, a rate significantly higher (P < 0.001) than that in men (5.9%).
Altogether, the proportions of subjects still receiving at least one psychoactive drug >10 years after alcohol withdrawal was 23.5%, less in men than in women (19.0 vs 42.1% P < 0.001).
How patients evaluated their medication
Analysis in the next section concerns only the 255 patients who were receiving at least one psychoactive medication including the small number receiving a medicine for abstinence (i.e. licensed for alcohol dependence). For 78.9%, being on medication was regarded as a necessary support and it was almost never 'a reminder of the AUD' (82.4%) (Table 3) . It was considered as intended to cure the origin of the AUD by 66.1%, and as a cure of its consequences by 56.8%. Half (54.6%) claimed that it helped them to remain abstinent. In order to identify natural groupings of response profiles, we performed a cluster analysis on the 162 subjects who answered all items. Owing to the size of the cohort, the maximal number of clusters was set at four; as the item 'reminder of the AUD' was scored by only a few subjects, it was not entered into the model.
Results are presented in Fig. 2 . In Cluster 1 (29% of the responders), the reason for being on medication was poorly related to the items explored, with 57.4% only claiming it was a support, 23.4% and 10.6% claiming it was to treat the consequences of AUD and the symptoms having led to AUD, respectively, and never a help to remain abstinent. In Cluster 2 (17.9% of the responders), treatment was considered a support and a treatment of symptoms having led to AUD since this item was scored by all, and was never considered a help to avoid relapses. All subjects in Cluster 3 (30.2% of the responders) claimed that their treatment corresponded to all the items explored. Finally, the main reason for treatment in Cluster 4 (22.8% of the responders) was to help remain abstinent. Among the subjects who were not followed-up by a physician or a psychologist for their AUD, two-thirds (65.5%) belonged to Cluster 1. Subjects who were abstinent for a long time, i.e. >5 years, were mainly (71.4%) classified in Clusters 1 and 2, while those who stopped alcohol for <1 year were in Clusters 3 and 4 (65.6%). The frequency of treatment with an anxiolytic, an anti-depressant, a hypnotic was similar in the four clusters. Conversely, the rates of medication licensed to maintaining abstinence were significantly (P < 0.01) higher in Clusters 3 and 4 (46.9 and 32.4%, respectively) as compared to 1 and 2 (6.4 and 24.1%, respectively).
Self-evaluation of dependence on medication
Among the 255 subjects on medication, 182 answered this question. The mean dependence score was 3.04 ± 1.7 and did not vary according to the length of abstinence or between the four clusters identified.
When being dependent was defined as a score ≥4 (maximal score = 5), 43.1% of the responders fell in this category. Women were more frequently dependent than men (54.7 vs 39.0%, P = 0.04).
The rate of dependence varied from 37% at year 1 to 57% at year 5 and more, but the difference was not statistically significant. Dependent patients were more frequently treated with hypnotics (38.3 vs 21.8%, P = 0.02) while there was no difference regarding antidepressants and anxiolytics.
DISCUSSION
Alcoholism is a chronic disease frequently associated with anxiety and depression (Kushner et al., 1990; Grant and Harford, 1995) . Following alcohol withdrawal, it takes several years before actual stabilization is obtained. Indeed in those who are completely abstinent 1 year after withdrawal, the probability of relapse progressively tends to zero but is still~0.20 at year 5 after detoxification (Mertensa et al., 2012) .
Therefore, it is not surprising to observe that in our survey the rate of prescribed medication remained high during the first years following stopping drinking. Analysis of our data according to the duration of abstinence showed that the most rapidly declining prescription concerned the medications for abstinence which were no longer given 5 years after withdrawal and this was consistent with the natural history of abstinence. In men, prescription of antidepressant and anti-anxiety medication decreased slowly but regularly over the years following alcohol withdrawal; conversely in women, the rate of anti-depressant and anti-anxiety prescriptions or increased slightly during the 5 years following withdrawal and decreased later than in man; these results are consistent with those we observed in a population of alcoholics attending to specialized care center (Nalpas et al., 2016) . Nevertheless, 10 years and more after having stopped drinking, that is 37.5% of our study sample, a quarter of the women and 1 man out of 10 were still receiving an anxiolytic, that was more than three times higher than in the general French population of similar age (4.9% in men and 10.0% in women, unpublished data extracted by the author from the Baromètre Santé 2010 database); moreover the same can be said for antidepressants (3.3% in men and 9.2% in women from the general population).
The major category of anxiolytics prescribed was benzodiazepine and almost all subjects received it for >6 months. But in patients with AUD, benzodiazepines are indicated for managing the symptoms of alcohol withdrawal, which is a very short period of time, and they are not recommended for long-term use after detoxification. They are advised with caution for patients with comorbid anxiety disorders (Lejoyeux et al., 1998; Mueller et al., 2005) . Indeed pharmacological dependence on benzodiazepine is a medical reality (Lader, 1983) and benzodiazepine use has been reported to be associated with an increased risk of Alzheimer's disease (Billioti de Gage et al., 2014) , so this argues against prolonged use in patients with a background of dependence and at high risk of mental disorders due to both old age and the residual consequences of alcoholism on their brain.
One reason for such a long prescription could be that long-term abstinent subjects (>10 years) had been patients with 'secondary alcoholism', so their mood/anxiety disorder still needed treatment (Schuckit, 1985) . In a large study of the subjects with past diagnosed, i.e. >12 months before the survey at least, alcohol dependence 7.6% had a past-year diagnosis of major depression (Hasin and Grant, 2002) . The research team of Fein analyzed the prevalence of psychiatric comorbidities in alcoholism in two different studies. In the first study (Fein, 2013) , including middle aged alcoholics (mean 48.7 years) current mood disorders were observed iñ 30% of women and 20% of men who had been abstinent since an average of 6.9 years, whilst the prevalence of anxiety disorders was 19% and 7% in women and men, respectively; these figures are close to the rates for the use of anxiolytics in our sub-group of subjects who had been abstinent <10 years and who were of similar age. In a second study (Fein et al., 2008) , 4.8% of older alcoholics (mean age = 67.5 years), abstinent for a very long time (mean = 14.8 years), had a current psychiatric diagnosis. Our sample was similar to the latter in terms of age and duration of abstinence, but if we considered that all subjects treated had a psychiatric disorder, its prevalence in our sample would be more than five times higher, a hypothesis which cannot be completely excluded but which seems unlikely.
In our series, women were more frequently treated than men, before and after alcohol withdrawal, and were more frequently given anti-depressant medications. Such a result is likely to be related to the known increased prevalence of depression in women as compared to men (Kessler, 2003) , an epidemiologic phenomenon still not well understood (Piccinelli and Wilkinson, 2000; Boden and Fergusson, 2011; Altemus et al., 2014) . The fact that alcoholic women speak more about depression than men (Abulseoud et al., 2013) could also explain their higher rate of treatment.
Another reason for long-term prescription might well be precautionary. Many patients entering treatment for substance misuse are already prescribed a wide range of psychotropic medicines (Foulds et al., 2016) . In the event of primary alcoholism, i.e. when alcoholism precedes psychiatric disorders, the symptoms of mood disorder and/or anxiety disorder, evaluated using the Hospital Anxiety Depression (HAD) score (Zigmond and Snaith, 1983) , rapidly decrease after detoxification and HAD scores are close to normal~5 years later (Allan, 1995; Wetterling and Junghanns, 2000; Driessen et al., 2001; Liappas et al., 2002) . But patients as well as physicians, fearing relapse, maintain the medication to preserve an equilibrium still considered as fragile; an argument in favor of this hypothesis is that patients not being specifically followed-up for their AUD were prescribed psychoactive medications less often. Although there is no reason for prescription of any medication if the AUD is denied or patients consider themselves to be recovered, over-prescription should not be considered a preposterous strategy since psychoactive medication is viewed positively by some patients (Baumann et al., 2001 (Baumann et al., , 2004 and a large cost study of alcohol pharmacotherapy showed that patients who received medications licensed for the treatment of alcohol dependence had lower healthcare utilization and total costs for treatment of alcohol dependence than patients who did not (Baser et al., 2011) .
Although we did not know the medical reasons for prescription (we had not asked for diagnoses), the opinion of the patients on their treatment brought important data. Cluster analysis identified four sub-groups of perception despite a rather similar medication profile, except for medication for abstinence. In Cluster 1, about half of the subjects claimed that the only reason for taking a pill was as a support and rarely for the treatment of the causes or consequences of AUD; for all the other subjects in this cluster, the treatment was not for any of the proposed reasons. Moreover, most of the patients of this cluster did not have any specific medical followup for their AUD or were still abstinent for a very long time. Therefore, it can be supposed that they represented subjects for whom medication is taken as a precaution and it could be stopped.
In subjects of Cluster 2, medication was a support but also a treatment of psychiatric symptoms preceding the onset of AUD; in this sub-group, the rate of subjects receiving anxiolytics, antidepressants or hypnotics was the highest when compared to the other groups, although the difference was not statistically significant. In these patients, AUD might well be a comorbidity of a former psychiatric disorder which still needed to be treated. Clusters 3 and 4 grouped together the majority of subjects who had stopped drinking for <1 and 5 years; in Cluster 3, all the reasons justified the medication and this could correspond to subjects with low self-confidence and a rather high risk of relapse, while in Cluster 4 the main reason for being treated was to avoid relapse; it might be dangerous to stop medication in these subjects.
About half of the patients considered they were dependent on their medication. Maybe this figure would be different if dependence had been assessed using a validated scale such as the DSM. However, acknowledging dependence might well suggest that the corresponding subjects are not yet ready to stop their medication. Dependence rate was not modulated by the duration of abstinence or by the reasons for treatment (assessed by the cluster analysis) but was significantly associated with female sex and being treated by a hypnotic. Regarding female sex, this could be related to the higher rate of medication in women and a higher severity of mood disorders when compared to men. Sleep disturbances are frequent following alcohol withdrawal (Perney et al., 2012) and for some still present >2 years on (Drummond et al., 1998) ; moreover, the persistence of insomnia for months is a predictor of alcohol relapse (Clark et al., 1998; Drummond et al., 1998) . Abstinent alcoholics are aware of the potentially harmful consequences of insomnia and it is not surprising that some feel the need for hypnotics.
Our study has several limitations. First, our study sample was not randomly constituted, it was a 'convenience sample', but we were unbiassed in approaching associations and the locations of the meetings. The questionnaire was not presented as specifically related to medication use. We cannot state how representative our sample was, but abstainers are a population difficult to access for such a study. Second, we had no information about the psychiatric history of the responders: as well as testing the willingness of participants to reveal very private information, the information may have had only spurious accuracy given the varied language in which emotional disorders are described. Finally, although the total number of responders was large enough, the size of sub-groups in the cluster analysis was rather small. Therefore, our results should indeed be regarded with caution but they also highlight that long-term medication after stopping drinking is an important question in medical practice. To shed light on this crucial point, clinical trials enrolling long-term abstainer and comparing the impact of stopping medication on abstinence and quality of life would be welcome.
In conclusion, our study showed that psychoactive medication is prescribed in France for years after stopping drinking, specifically anxiolytics and antidepressants, and more to women than men. In about a third of the patients, mainly those having stopped drinking for a very long time and those having no specific medical follow-up for their alcoholic disorders, over-prescription might be suspected, an hypothesis to which our work cannot definitely answer but which merits to be addressed in future research. However, as feeling 'dependent' on their medication is prevalent in long-term abstainers, any change in on-going treatment should be clearly explained and implemented with caution to avoid psychological disturbance which could impair abstinence status.
